AU2002235175A1 - Lometrexol combination therapy - Google Patents

Lometrexol combination therapy

Info

Publication number
AU2002235175A1
AU2002235175A1 AU2002235175A AU3517502A AU2002235175A1 AU 2002235175 A1 AU2002235175 A1 AU 2002235175A1 AU 2002235175 A AU2002235175 A AU 2002235175A AU 3517502 A AU3517502 A AU 3517502A AU 2002235175 A1 AU2002235175 A1 AU 2002235175A1
Authority
AU
Australia
Prior art keywords
lometrexol
combination therapy
therapy
combination
lometrexol combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002235175A
Inventor
Alan Hilary Calvert
David R. Newell
Jacqueline Mary Walling
Heather Kay Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tularik Inc
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Publication of AU2002235175A1 publication Critical patent/AU2002235175A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
AU2002235175A 2000-12-06 2001-12-05 Lometrexol combination therapy Abandoned AU2002235175A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25403000P 2000-12-06 2000-12-06
US60254030 2000-12-06
US26113401P 2001-01-11 2001-01-11
US60261134 2001-01-11
PCT/US2001/047299 WO2002045717A1 (en) 2000-12-06 2001-12-05 Lometrexol combination therapy

Publications (1)

Publication Number Publication Date
AU2002235175A1 true AU2002235175A1 (en) 2002-06-18

Family

ID=26943782

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002235175A Abandoned AU2002235175A1 (en) 2000-12-06 2001-12-05 Lometrexol combination therapy

Country Status (3)

Country Link
US (1) US20020156023A1 (en)
AU (1) AU2002235175A1 (en)
WO (1) WO2002045717A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0797988T3 (en) 1993-07-19 2009-05-11 Univ British Columbia Anti-angiogenic compositions and methods for their use
NZ532593A (en) * 2001-10-25 2007-11-30 Wisconsin Alumni Res Found Vascular stent or graft coated or impregnated with protein tyrosine kinase inhibitors and method of using same
EP1944026B1 (en) * 2002-05-16 2013-06-26 Novartis AG Use of EDG receptor binding agents in cancer
US20040096436A1 (en) * 2002-08-02 2004-05-20 Regents Of The University Of California Methods for inhibiting protein kinases in cancer cells
FR2844452A1 (en) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Modulating dendritic cell activity, e.g. for treatment of viral infections, NK-sensitive tumors or autoimmune diseases, using inhibitors or specific tyrosine kinases, e.g. c-abl, bcr/abl and c-kit
CA2513260C (en) * 2003-01-31 2013-01-08 Childrens Hospital Los Angeles Oral compositions of fenretinide having increased bioavailability and methods of using the same
US7635673B2 (en) * 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
WO2005016241A2 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
EP2263694B1 (en) * 2003-09-25 2013-06-12 Astellas Pharma Inc. Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7022350B2 (en) * 2004-02-26 2006-04-04 Proethic Pharmaceuticals, Inc. Dietary supplement
CA2503554A1 (en) * 2004-04-27 2005-10-27 Proethic Laboratories, Llc Dietary supplement
ATE501252T1 (en) * 2004-06-22 2011-03-15 Univ Illinois METHOD FOR INHIBITING TUMOR CELL GROWTH USING FOXM1 SIRNS
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060068037A1 (en) * 2004-09-29 2006-03-30 Proethic Laboratories, L.L.C. Admixing process for making compositions containing vitamin E and saw palmetto
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
US20100056441A1 (en) * 2006-03-17 2010-03-04 Costa Robert H Method for Inhibiting Angiogenesis
US8029980B2 (en) * 2006-09-29 2011-10-04 The Board Of Trustees Of The University Of Illinois Identification and use of agents that modulate oncogenic transcription agent activity
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US8263340B2 (en) * 2007-03-20 2012-09-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Constitutively active mutants of the prolactin receptor
FR2945747A1 (en) 2009-05-25 2010-11-26 Centre Nat Rech Scient ANTITUMOR PHARMACEUTICAL COMPOSITION COMPRISING A CDKS INHIBITOR AND A CELL GROWTH INHIBITOR
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
CN103747795A (en) 2011-06-07 2014-04-23 美索布拉斯特国际有限公司 Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
BR112017024356A2 (en) * 2015-05-13 2018-07-31 Monopar Therapeutics Inc clonidine and / or clonidine derivatives for use in the prevention of radiotherapy skin damage

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217974A (en) * 1991-03-29 1993-06-08 Eli Lilly And Company Method for treating gar-transformylase tumors in mammals and reducing mammalian toxicity
US5594139A (en) * 1993-01-29 1997-01-14 Agouron Pharmaceuticals, Inc. Processes for preparing antiproliferative garft-inhibiting compounds

Also Published As

Publication number Publication date
US20020156023A1 (en) 2002-10-24
WO2002045717A1 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
AU2002327620A1 (en) Defibrillators
AU2002223827A1 (en) Well treatment
AU2002235175A1 (en) Lometrexol combination therapy
AU2002359163A1 (en) New use
AU2002313565A1 (en) Putter-heads
AU2002300754A1 (en) New Combination
AU2002319650A1 (en) Defibrillators
AU2002335667A1 (en) Modified reoviral therapy
AU2002313943A1 (en) Electromobile
AU2001292897A1 (en) Novel therapy
AU2002226571A1 (en) Biligands
AU2001100406A4 (en) DriverSMS
AU2002245337A1 (en) Epoxyvibsanin b
AU2002313073A1 (en) Phytocystatin
AU2002257925A1 (en) Numberplates
AUPR223700A0 (en) Therapeutic methods - ii
AUPR969801A0 (en) Therapeutic compounds - ii
AU2001100214A4 (en) Dolly-trolley
AU2002100746A4 (en) Adrail
AU2001100338A4 (en) Sunglove
AU2001100532A4 (en) FonePark
AU2001100522A4 (en) e-Trans
AUPR325301A0 (en) Easy build - mpt - system
AU2002317838A1 (en) Plasma-accelerator configuration
AUPR243601A0 (en) Improvements